Protagonist Therapeutics Inc(PTGX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The company is headquartered in Newark California, California and currently employs 70 full-time employees. The firm's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Current Price

$28.02

RSI

52.003

Beta:

1.550739

March 10, 2021
6M
-19M

-101.383 %
-3833.182 %
-13.464 %
-13.226 %

$-1,093,600
$-113,000
$0
$62,000
$-34,000
-89.667 %
-100.000 %
-Infinity %
154.839 %

$-64,845,000
$-77,878,000
$-39,723,000
$-38,857,000
$-50,577,000
20.099 %
-48.993 %
-2.180 %
30.162 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.